Stock Information

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing differentiated therapies for oncology and central nervous system disorders.

The Company is advancing a focused pipeline of high-value assets supported by strong scientific rationale, clinical validation, and clearly defined regulatory pathways.

Pipeline Overview

NDV-01 is a sustained-release intravesical formulation of gemcitabine and docetaxel (Gem/Doce) for the treatment of non-muscle invasive bladder cancer (NMIBC). The program has demonstrated compelling clinical activity with durable responses and a favorable safety profile and is advancing into Phase 3 registrational development across two distinct indications.

Strategy

Relmada is focused on advancing its pipeline through disciplined clinical execution and key regulatory milestones, with an emphasis on:

• Delivering durable efficacy, favorable safety, and real-world usability
• Advancing programs with clear and efficient development pathways
• Supporting broad clinical adoption across large and well-defined patient populations

The Company also evaluates additional opportunities that align with its strategy of developing differentiated therapies with strong clinical and commercial potential.

Company Overview

Founded in 2004 and headquartered in Coral Gables, Florida, Relmada Therapeutics is committed to building a pipeline of innovative therapies designed to deliver meaningful outcomes for patients and long-term value for shareholders.